Charles River Validates Virtual Control Groups in Toxicology Studies
Event summary
- Charles River published a retrospective analysis in Regulatory Toxicology and Pharmacology showing 100% concordance in NOAEL across 20 toxicology studies using virtual control groups (VCGs) instead of concurrent control groups (CCGs).
- VCGs reduced animal use by up to 25% without compromising regulatory-grade rigor in the studies reviewed.
- Charles River joined the VICT3R Project in 2025 to mainstream VCG adoption in toxicology.
- The European Medicines Agency issued a draft qualification for VCGs in dose-range finding studies.
The big picture
Charles River's validation of VCGs aligns with broader industry shifts toward animal-free research methods and data-driven toxicology. The collaboration with regulators and consortia like VICT3R signals growing acceptance of alternative methodologies, potentially reshaping nonclinical safety assessment standards. The success of this approach could accelerate the approval of new therapies while reducing ethical and operational challenges associated with animal testing.
What we're watching
- Regulatory Adoption
- The pace at which the European Medicines Agency and other regulators formalize VCG guidelines will determine industry-wide adoption rates.
- Competitive Differentiation
- Whether Charles River can sustain its lead in VCG technology as competitors develop similar alternatives.
- Client Conversion
- How quickly biopharma companies transition from traditional control groups to VCGs in their safety studies.